A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

NCT01229215 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy

Interventions

DRUG: FCFD4514S
DRUG: sham

Sponsor

Genentech, Inc.